还原型谷胱甘肽联合甘草酸二铵治疗非酒精性脂肪肝的临床研究

目的 探讨还原型谷胱甘肽联合甘草酸二铵治疗非酒精性脂肪肝的临床疗效。方法 选择2017年3月—2019年3月在南通大学附属如皋医院治疗的120例非酒精性脂肪性肝病患者，随机分为对照组和治疗组，每组各60例。对照组口服甘草酸二铵肠溶胶囊，150 mg/次，3次/d。治疗组在对照组基础上肌肉注射注射用还原型谷胱甘肽，2支/d。两组患者均治疗12周。观察两组患者临床疗效，比较治疗前后两组患者谷氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、总胆固醇（TC）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）、三酰甘油（TG）、谷胱甘肽过氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）和丙二醛（MDA）水平。结果 治疗后，治疗组临床有效率（93.33%）明显高于对照组（79.66%,P<0.05）。治疗后，两组AST、ALT、TC、TG、LDL-C和MDA水平均较治疗前明显下降，而HDL-C、GSH-Px和SOD水平明显升高（P<0.05），且治疗组这些指标水平明显好于对照组（P<0.05）。结论 还原型谷胱甘肽联合甘草酸二铵治疗非酒精性脂肪肝病的疗效明显。

Clinical study on reduced glutathione combined with diammonium glycyrrhizinate in treatment of non-alcoholic fatty liver

Objective To investigate the curative effect of reduced glutathione combined with diammonium glycyrrhizinate in treatment of non-alcoholic fatty liver. Methods Patients (120 cases) with non-alcoholic fatty liver in Rugao Hospital Affiliated to Nantong University from March 2017 to March 2019 randomly were divided into control and treatment group, and each group had 60 cases. Patients in the control group was po administered with Diammonium Glycyrrhizinate Enteric-coated Capsules, 150 mg/time, three times daily. Patients in the treatment group were im administered with Reduced Glutathione for injection on the basis of the control group, 2 injections/d. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the levels of AST, ALT, TC, TG, LDL-C, HDL-C, GSH-Px, SOD, and MDA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (93.33%) was significantly higher than that of the control group (79.66%, P < 0.05). After treatment, the levels of AST, ALT, TC, TG, LDL-C, and MDA in two groups were significantly lower than those before treatment, while the levels of HDL-C, GSH-Px, and SOD were significantly increased (P < 0.05), and these indexes level in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Reduced glutathione combined with diammonium glycyrrhizinate is effective in treating non-alcoholic fatty liver non-alcoholic fatty liver disease.